Responses
Rheumatoid arthritis
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
Compose a Response to This Article
Other responses
No responses have been published for this article.